Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

• Sonja Zweegman,
• Claudia A.M. Stege,
• Einar Haukas,
• Fredrik H. Schjesvold,
• Mark-David Levin,
• Anders Waage,
• Rineke B.L. Leys,
• Saskia K. Klein,
• Damian Szatkowski,
• Per Axelsson,
• Trung Hieu Do,
• Dorota Knut-Bojanowska,
• Ellen van der Spek,
• Asta Svirskaite,
• Anja Klostergaard,
• Morten Salomo,
• Celine Blimark,
• Paula F. Ypma,
• Ulf-Henrik Mellqvist,
• Pino J. Poddighe,
• Marian Stevens-Kroef,
• Niels W.C.J. van de Donk,
• Pieter Sonneveld,
• Markus Hansson,
• Bronno van der Holt,
• Niels Abildgaard

Affiliations

Sonja Zweegman

Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands;

Claudia A.M. Stege

Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands;

Einar Haukas

Stavanger University Hospital-Rogaland Hospital, Stavanger, Norway;

Fredrik H. Schjesvold

Oslo Myeloma Center, Oslo, Norway;

Mark-David Levin

Albert Schweitzer Hospital, Dordrecht, the Netherlands;

Anders Waage

St Olavs Hospital and Norwegian University of Science, Trondheim, Norway;

Rineke B.L. Leys

Maasstad Hospital, Rotterdam, the Netherlands;

Saskia K. Klein

Meander Medical Center, Amersfoort, the Netherlands;

Damian Szatkowski

Førde Central Hospital, Førde, Norway;

Per Axelsson

Skanes University Hospital Lund, Scania, Sweden;

Trung Hieu Do

Herlev Hospital, Herlev, Denmark;

Dorota Knut-Bojanowska

NU-Hospital, Uddevalla Hospital, Uddevalla, Sweden;

Ellen van der Spek

Rijnstate Hospital, Arnhem, the Netherlands;

Asta Svirskaite

Aalborg Hospital, Aalborg, Denmark;

Anja Klostergaard

Aarhus University Hospital, Aarhus, Denmark;

Morten Salomo

Rigshospitalet Copenhagen, Copenhagen, Denmark;

Celine Blimark

Sahlgrenska University Hospital, Gothenburg Sweden;

Paula F. Ypma

Haga Hospital, Den Haag, the Netherlands;

Ulf-Henrik Mellqvist

Sodra Alvsborgs Sjukhus Boras, Boras, Sweden;

Pino J. Poddighe

Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands;

Marian Stevens-Kroef

Radboud Medical Center, Nijmegen, the Netherlands;

Niels W.C.J. van de Donk

Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands;

Pieter Sonneveld

Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands;

Markus Hansson

Skanes University Hospital Lund, Scania, Sweden;

Bronno van der Holt

Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands;

Niels Abildgaard

Department of Haematology, AgeCare, Odense University Hospital, Odense, Denmark